LeonaBio, Inc. ( LONA ) Discusses Modulation and Combination Strategies in ER-Positive Metastatic Breast Cancer and the Role of Lasofoxifene April 29, 2026 12:00 PM EDT Company Participants Mark Litton - President, CEO & Director Conference Call Participants David Portman - Sermonix Pharmaceuticals, Inc. Matthew P. Goetz Seth Wander Daniel Bronder - Cantor Fitzgerald & Co., Research Division Douglas Macpherson - Mizuho Securities USA LLC, Research Division Thomas Shrader - BTIG, LLC Presentation Operator Good afternoon, and thank you for joining LeonaBio's key opinion leader call. [Operator Instructions] A replay of today's event will be available on the Investors section of the LeonaBio website. I would now like to turn the call over to Mark Litton, President and CEO of LeonaBio. Mark Litton President, CEO & Director Thank you, Elissa, and good afternoon, everyone. I'm Mark Litton, President and CEO of LeonaBio.…